NZ602612A - Novel benzamide derivatives - Google Patents

Novel benzamide derivatives

Info

Publication number
NZ602612A
NZ602612A NZ602612A NZ60261211A NZ602612A NZ 602612 A NZ602612 A NZ 602612A NZ 602612 A NZ602612 A NZ 602612A NZ 60261211 A NZ60261211 A NZ 60261211A NZ 602612 A NZ602612 A NZ 602612A
Authority
NZ
New Zealand
Prior art keywords
disease
methoxybenzamide
piperidin
chloro
amino
Prior art date
Application number
NZ602612A
Other languages
English (en)
Inventor
Hyun-Jung Sung
Kang-Hun Cho
Weon-Bin Im
Soon-Hoe Kim
Sung-Hak Choi
Ju-Hee Sohn
Sun-Ho Choi
Mi-Yeon Kim
Tae-Kyoung Sohn
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of NZ602612A publication Critical patent/NZ602612A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
NZ602612A 2010-04-23 2011-04-18 Novel benzamide derivatives NZ602612A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100038039A KR101180174B1 (ko) 2010-04-23 2010-04-23 신규한 벤즈아미드 유도체
PCT/KR2011/002759 WO2011132901A2 (en) 2010-04-23 2011-04-18 Novel benzamide derivatives

Publications (1)

Publication Number Publication Date
NZ602612A true NZ602612A (en) 2014-11-28

Family

ID=44834616

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ602612A NZ602612A (en) 2010-04-23 2011-04-18 Novel benzamide derivatives

Country Status (19)

Country Link
US (1) US9221790B2 (enExample)
EP (1) EP2560955B1 (enExample)
JP (1) JP5564147B2 (enExample)
KR (1) KR101180174B1 (enExample)
CN (1) CN102844301B (enExample)
AU (1) AU2011243393B2 (enExample)
BR (1) BR112012026509B1 (enExample)
CA (1) CA2794176C (enExample)
ES (1) ES2594708T3 (enExample)
IL (1) IL222491A (enExample)
MX (1) MX2012011721A (enExample)
MY (1) MY162554A (enExample)
NZ (1) NZ602612A (enExample)
PH (1) PH12012501843A1 (enExample)
RU (1) RU2536688C2 (enExample)
SG (1) SG184350A1 (enExample)
UA (1) UA107702C2 (enExample)
WO (1) WO2011132901A2 (enExample)
ZA (1) ZA201207903B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물
KR101457789B1 (ko) 2013-02-13 2014-11-03 동아제약 주식회사 상처 치료용 필름형성 약제학적 조성물 및 그의 제조방법
US9771348B2 (en) 2013-07-25 2017-09-26 Dong-A St Co., Ltd Method for preparing benzamide derivative, novel intermediate used in preparation of benzamide, and method for preparing novel intermediate
CN104230889A (zh) * 2014-08-29 2014-12-24 南京大学 环丙沙星衍生物及其制备方法与用途
KR102394635B1 (ko) * 2015-03-31 2022-05-09 (주)아모레퍼시픽 5-아다만탄-1-일-n-(2,4-다이하이드록시벤질)-2,4-다이메톡시벤즈아마이드를 함유하는 항산화 또는 항노화 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507462A (en) 1974-03-21 1978-04-12 Gallardo Antonio Sa N-heterocyclic substituted benzamides methods for their preparation and compositions containing them
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5057525A (en) 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
US5137896A (en) 1981-10-01 1992-08-11 Janssen Pharmaceutica N.V. N-(3-hydroxy-4-piperidinyl)benzamide derivatives
EP0774460A1 (en) 1994-03-30 1997-05-21 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compound and use thereof as medicine
US5864039A (en) * 1994-03-30 1999-01-26 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and use thereof as medicaments
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
KR20010081034A (ko) * 1998-11-20 2001-08-25 프리돌린 클라우스너, 롤란드 비. 보레르 피페리딘 씨씨알-3 수용체 길항제
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
KR100976063B1 (ko) 2007-03-16 2010-08-17 동아제약주식회사 신규한 벤즈아미드 유도체 화합물 및 그의 제조방법
ES2526338T3 (es) 2007-04-19 2015-01-09 Dong-A Pharm.Co., Ltd. Inhibidor de DPP-IV que incluye grupo beta-amino, método de preparación del mismo y composición farmacéutica que contiene el mismo para prevernir y tratar diabetes u obesidad
US8642772B2 (en) * 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
WO2010062959A1 (en) 2008-11-26 2010-06-03 Aryx Therapeutics, Inc. 5-ht4 receptor agonists for treating irritable bowel syndrome and colonic hypersensitivity
BR112012023139A2 (pt) 2010-03-24 2018-06-26 Dong A Pharm Co Ltd composição farmacêutica para a prevenção ou o tratamento de doença do fígado gordo não alcóolico e o método para a prevenção ou tratamento de doença do fígado gordo não alcóolico usando a mesma.
SG190415A1 (en) 2010-11-24 2013-06-28 Dong A St Co Ltd Quinoline derivative compound, method for preparing same, and pharmaceutical composition containing same
JP5599519B2 (ja) 2010-11-24 2014-10-01 ドン−ア エスティ カンパニー リミテッド キノリン誘導体化合物、その製造方法およびそれを含む薬学組成物
KR101341693B1 (ko) 2011-03-16 2013-12-16 동아에스티 주식회사 생약추출물을 함유하는 퇴행성 신경질환의 치료 및 예방을 위한 조성물
KR101341692B1 (ko) 2011-03-16 2013-12-20 동아에스티 주식회사 복합생약추출물을 함유하는 당뇨병성 말초 신경병증의 치료 및 예방을 위한 조성물

Also Published As

Publication number Publication date
MX2012011721A (es) 2012-12-17
CA2794176C (en) 2015-12-15
RU2536688C2 (ru) 2014-12-27
BR112012026509B1 (pt) 2021-01-19
CN102844301B (zh) 2015-04-22
RU2012150037A (ru) 2014-05-27
KR101180174B1 (ko) 2012-09-05
EP2560955A4 (en) 2013-09-11
US20130085160A1 (en) 2013-04-04
MY162554A (en) 2017-06-15
AU2011243393A1 (en) 2012-10-18
WO2011132901A2 (en) 2011-10-27
AU2011243393B2 (en) 2014-07-17
ZA201207903B (en) 2013-06-26
BR112012026509A2 (pt) 2017-10-31
IL222491A0 (en) 2012-12-31
JP5564147B2 (ja) 2014-07-30
SG184350A1 (en) 2012-11-29
CA2794176A1 (en) 2011-10-27
WO2011132901A3 (en) 2012-01-26
PH12012501843A1 (en) 2013-01-07
IL222491A (en) 2016-07-31
EP2560955B1 (en) 2016-06-29
UA107702C2 (xx) 2015-02-10
CN102844301A (zh) 2012-12-26
KR20110118446A (ko) 2011-10-31
JP2013525344A (ja) 2013-06-20
US9221790B2 (en) 2015-12-29
EP2560955A2 (en) 2013-02-27
ES2594708T3 (es) 2016-12-22
HK1176061A1 (en) 2013-07-19

Similar Documents

Publication Publication Date Title
NO20073566L (no) Oksyindol-derivater som agonister for 5HT4-reseptor
NO20061519L (no) Benzimiflazolonforbindelser som har 5HT4-reseptorantagonistisk aktivitet
EA010891B9 (ru) Производные бензимидазолонкарбоновой кислоты
UY29421A1 (es) Nuevos compuestos de n-(n-sulfonilaminoarilmetil) ciclopropanocarboxanida sustituidos, comoposiciones farmacéuticas que los contienen a aplicaciones.
NZ597125A (en) Gpr119 agonists
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
MX2010003001A (es) Derivados de quinolina como antagonistas del receptor de la 5-hidroxitriptamina 5a.
NO20080445L (no) Nye azetidinderivater som neurokininreseptorantagonister for behandling av gastrointestinale sykdommer
NO20091054L (no) Benzimidazolderivater anvendelige for behandling av vallinoidreceptor TRPV1 relaterte forstyrrelser
RU2009138219A (ru) Новые бензамидные производные и способ их получения
EP2548874A3 (en) Substituted piperazines as CB1 antagonists
MX2009009121A (es) Aminoamidas como antagonistas de orexina.
ZA200810031B (en) 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use for the manufacture of medicaments
ATE449092T1 (de) Indazolcarbonsäureamidderivate als agonisten des 5ht4-rezeptors
NO20084674L (no) 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
EA201001645A1 (ru) Хинуклидиновые производные в качестве антагонистов мускаринового м3 рецептора
EA200870591A1 (ru) 2-фенил-5-амино-1,3,4-оксадиазолы и их применение в качестве лигандов никотинового рецептора ацетилхолина
WO2006041985A3 (en) Thienopyridinone compounds and methods of treatment
CA2559530C (en) Novel benzyl(idene)-lactam derivatives
MX2010004300A (es) Ligandos de (1,4-diaza-biciclo [3,2,2]non-6-en-4-il)-heterociclil- metanona para receptores nicotinicos de acetilcolina, utiles para el tratamiento de enfermedad.
WO2006120478A3 (en) Quinoline derivatives as neurokinin receptor antagonists
RU2012150037A (ru) Новые бензамидные производные
JP2013525344A5 (enExample)
MX2012001799A (es) Derivados de pirrolidina como antagonistas del receptor de neuroquinona 3 (nk3).
JPWO2009104729A1 (ja) アミド誘導体及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2016 BY HENRY HUGHES IP LIMITED

Effective date: 20150608

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 APR 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20160311

LAPS Patent lapsed